12:00 AM
Dec 24, 2012
 |  BC Week In Review  |  Company News  |  Deals

Cardiome, Merck deal

Cardiome agreed to pay former partner Merck $20 million by March 31, 2013, to settle $50 million in debt obligations under an amended 2009 deal to develop and commercialize IV and oral formulations of atrial fibrillation (AF) product vernakalant. In September, Merck said it would return all rights to develop and commercialize both formulations to Cardiome, terminating the 2009 deal. As part of...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >